Filter Results:
- Full text PDF available (7)
Publication Year
2016
2018
- This year (4)
- Last 5 years (21)
- Last 10 years (21)
Publication Type
Co-author
Journals and Conferences
Learn More
- Anna Gluba-Brzózka, Marta Michalska-Kasiczak, +4 authors Jacek Rysz
- Lipids in Health and Disease
- 2016
The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among leading causes of death and premature mortality of patients with chronic kidney disease. Even the… (More)
- Anna Gluba-Brzózka, Beata Franczyk, Peter P. Toth, Jacek Rysz, Maciej Banach
- Archives of medical science : AMS
- 2016
Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as… (More)
- Jacek Rysz, Anna Gluba-Brzózka, Beata Franczyk, Zbigniew Jabłonowski, Aleksandra D. Ciałkowska-Rysz
- International journal of molecular sciences
- 2017
In its early stages, symptoms of chronic kidney disease (CKD) are usually not apparent. Significant reduction of the kidney function is the first obvious sign of disease. If diagnosed early (stages 1… (More)
- Jacek Rysz, Beata Franczyk, Maciej Banach, Anna Gluba-Brzózka
- Current pharmaceutical design
- 2017
The prevalence of hypertension (HTN) worldwide is high and is constantly rising. HTN is considered to be a silent killer since often there are no obvious symptoms but long-term, HTN significantly… (More)
- Anna Gluba-Brzózka, Beata Franczyk, Jacek Rysz
- Nutrients
- 2017
Healthy diet is highly important, especially in patients with chronic kidney disease (CKD). Proper nutrition provides the energy to perform everyday activities, prevents infection, builds muscle, and… (More)
- Jacek Rysz, Beata Franczyk, Aleksandra D. Ciałkowska-Rysz, Anna Gluba-Brzózka
- Nutrients
- 2017
The prevalence of chronic kidney disease (CKD) is high and it is gradually increasing. Individuals with CKD should introduce appropriate measures to hamper the progression of kidney function… (More)
- Beata Franczyk, Anna Gluba-Brzózka, Jacek Rysz
- Current pharmaceutical design
- 2018
BACKGROUND
All stages of chronic kidney disease (CKD) are associated with increased risks of atherosclerosis and cardiovascular morbidity and mortality. According to studies, levels of copeptin,… (More)
- Anna Gluba-Brzózka, Marta Michalska-Kasiczak, +4 authors Jacek Rysz
- Lipids in Health and Disease
- 2016
- Piotr Bartnicki, Jacek Rysz, Beata Franczyk, Zbigniew Baj, Ewa Majewska
- Oxidative medicine and cellular longevity
- 2016
Background. Cardiovascular morbidity and mortality are very high in patients with chronic kidney disease (CKD). The purpose of this study is to evaluate the impact of continuous erythropoietin… (More)
- Jacek Rysz, Anna Gluba-Brzózka, Beata Franczyk, Maciej Banach, Piotr Bartnicki
- Expert opinion on pharmacotherapy
- 2016
INTRODUCTION
Despite progress in the understanding of pathogenetic mechanisms of organ cyst formation in autosomal dominant polycystic kidney disease, current treatment methods are insufficient.… (More)